IDEAYA Biosciences (IDYA) Q4 2025 earnings summary

Executive summary

• Achieved full enrollment in the Phase 2/3 OptimUM-02 trial for darovasertib and crizotinib in first-line HLA*A2-negative metastatic uveal melanoma; topline PFS results expected by late March 2026.

• Advanced clinical pipeline with multiple registrational trials planned for darovasertib across metastatic, neoadjuvant, and adjuvant uveal melanoma settings by H1 2026.

• Initiated IND filings for IDE034 and IDE574, and continued commercial readiness activities for darovasertib.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $1.05 billion as of December 31, 2025, expected to fund operations into 2030.

• Collaboration revenue for Q4 2025 was $10.9 million, up from $7.0 million in Q4 2024; full-year 2025 collaboration revenue was $218.7 million, up from $7.0 million in 2024.

• R&D expenses for Q4 2025 were $86.6 million, down from $140.2 million in Q4 2024; full-year R&D expenses were $314.7 million, up from $294.7 million in 2024.

• Net loss for Q4 2025 was $83.3 million, improved from $130.3 million in Q4 2024; full-year net loss was $113.7 million, improved from $274.5 million in 2024.

• G&A expenses for Q4 2025 were $18.8 million, up from $11.0 million in Q4 2024; full-year G&A expenses were $63.3 million, up from $39.3 million in 2024.

Outlook and guidance

• Topline PFS results from the OptimUM-02 trial expected by late March 2026, potentially enabling accelerated approval filing in the US.

• Darovasertib to be in three Phase 3 registrational trials across all uveal melanoma stages by H1 2026.

• Preliminary clinical data for IDE849 and initiation of its registrational study in SCLC/NEC targeted by end of 2026.

• Updated data for IDE397 in MTAP-deleted urothelial cancer expected at a 2026 medical conference.

• Cash runway expected to fund operations into 2030.